These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Effects of immunomodulators on the response induced by vaccines against autoimmune diseases. Marciani DJ Autoimmunity; 2017 Nov; 50(7):393-402. PubMed ID: 28906131 [TBL] [Abstract][Full Text] [Related]
26. A modern approach for epitope prediction: identification of foot-and-mouth disease virus peptides binding bovine leukocyte antigen (BoLA) class I molecules. Pandya M; Rasmussen M; Hansen A; Nielsen M; Buus S; Golde W; Barlow J Immunogenetics; 2015 Nov; 67(11-12):691-703. PubMed ID: 26496773 [TBL] [Abstract][Full Text] [Related]
27. Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes. Warrino DE; Olson WC; Knapp WT; Scarrow MI; D'Ambrosio-Brennan LJ; Guido RS; Edwards RP; Kast WM; Storkus WJ Clin Cancer Res; 2004 May; 10(10):3301-8. PubMed ID: 15161683 [TBL] [Abstract][Full Text] [Related]
28. Prophylactic herpes simplex virus type 2 vaccine adjuvanted with a universal CD4 T cell helper peptide induces long-term protective immunity against lethal challenge in mice. Li X; Zhang S; Lei J; Zhu Y; Zhou X; Xiao J; Xiang T Int Immunopharmacol; 2018 Aug; 61():100-108. PubMed ID: 29857239 [TBL] [Abstract][Full Text] [Related]
29. Molecular challenges imposed by MHC-I restricted long epitopes on T cell immunity. Josephs TM; Grant EJ; Gras S Biol Chem; 2017 Aug; 398(9):1027-1036. PubMed ID: 28141543 [TBL] [Abstract][Full Text] [Related]
31. Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo. Sin JI; Kim JJ; Zhang D; Weiner DB Hum Gene Ther; 2001 Jun; 12(9):1091-102. PubMed ID: 11399230 [TBL] [Abstract][Full Text] [Related]
32. Preventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope. Raafat N; Sadowski-Cron C; Mengus C; Heberer M; Spagnoli GC; Zajac P Int J Cancer; 2012 Sep; 131(5):E659-69. PubMed ID: 22116674 [TBL] [Abstract][Full Text] [Related]
33. Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1. Rosenthal KS; Mao H; Horne WI; Wright C; Zimmerman D Vaccine; 1999 Feb; 17(6):535-42. PubMed ID: 10075159 [TBL] [Abstract][Full Text] [Related]
34. Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen. Schroers R; Shen L; Rollins L; Xiao Z; Sonderstrup G; Slawin K; Huang XF; Chen SY Clin Cancer Res; 2003 Aug; 9(9):3260-71. PubMed ID: 12960111 [TBL] [Abstract][Full Text] [Related]
35. Rates of processing determine the immunogenicity of immunoproteasome-generated epitopes. Deol P; Zaiss DM; Monaco JJ; Sijts AJ J Immunol; 2007 Jun; 178(12):7557-62. PubMed ID: 17548590 [TBL] [Abstract][Full Text] [Related]
36. Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV. Kallinteris NL; Lu X; Wu S; Hu H; Li Y; Gulfo JV; Humphreys RE; Xu M Vaccine; 2003 Oct; 21(27-30):4128-32. PubMed ID: 14505892 [TBL] [Abstract][Full Text] [Related]
37. LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model. Rosenthal KS; Stone S; Koski G; Zimmerman DH J Immunol Res; 2017; 2017():3613505. PubMed ID: 28459074 [TBL] [Abstract][Full Text] [Related]
38. The role of T-cell-mediated mechanisms in virus infections of the nervous system. Dörries R Curr Top Microbiol Immunol; 2001; 253():219-45. PubMed ID: 11417137 [TBL] [Abstract][Full Text] [Related]
39. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. Steinman RM Mt Sinai J Med; 2001 May; 68(3):160-6. PubMed ID: 11373688 [TBL] [Abstract][Full Text] [Related]